Beam Therapeutics BEAM incurred a loss of $1.00 per share in the second quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of $1.04. The company had reported a loss of ...
Beam Therapeutics BEAM incurred a loss of 10 cents per share in the fourth quarter of 2025 (excluding gain on sale of equity method investment), narrower than the Zacks Consensus Estimate of a loss of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results